ReviewStem cell reviews and reports2015
Stem Cell Differentiation Toward the Myogenic Lineage for Muscle Tissue Regeneration: A Focus on Muscular Dystrophy.
Review in Stem cell reviews and reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 42 citations in OpenAlex.
- Recent advances in electroactive biomaterials and electrical stimulation for skeletal muscle regeneration: materials, strategies, and mechanistic insights.Materials today. Bio · 2026Review
- Fibrillar Bundles as Fibrous Filler Materials for Attaining Cell Anisotropy in Bioprinting.Advanced healthcare materials · 2026Article
- Nanofibrous Scaffolds' Ability to Induce Mesenchymal Stem Cell Differentiation for Soft Tissue Regenerative Applications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Skeletal Muscle Tissue Engineering: From Tissue Regeneration to Biorobotics.Cyborg and bionic systems (Washington, D.C.) · 2025Review
- Fabrication of Hydrogel-Based Composite Fibers and Computer Simulation of the Filler Dynamics in the Composite Flow.Bioengineering (Basel, Switzerland) · 2023Article
- Bioprinting and biomaterials for dental alveolar tissue regeneration.Frontiers in bioengineering and biotechnology · 2023Review
- Changes in Elastic Moduli of Fibrin Hydrogels Within the Myogenic Range Alter Behavior of Murine C2C12 and Human C25 Myoblasts Differently.Frontiers in bioengineering and biotechnology · 2022Article
- Cardiac Differentiation of Mesenchymal Stem Cells: Impact of Biological and Chemical Inducers.Stem cell reviews and reports · 2021Review
- A Promising Future for Stem-Cell-Based Therapies in Muscular Dystrophies-In Vitro and In Vivo Treatments to Boost Cellular Engraftment.International journal of molecular sciences · 2019Review
- Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy.Human molecular genetics · 2019Article
- 3D Bioprinting in Skeletal Muscle Tissue Engineering.Small (Weinheim an der Bergstrasse, Germany) · 2019Review
- Review
- Monitoring disease activity noninvasively in theProceedings of the National Academy of Sciences of the United States of America · 2018Article
- The Importance of Biophysical and Biochemical Stimuli in Dynamic Skeletal Muscle Models.Frontiers in physiology · 2018Review
- Anisotropic Materials for Skeletal-Muscle-Tissue Engineering.Advanced materials (Deerfield Beach, Fla.) · 2016Review
- Generation of human muscle fibers and satellite-like cells from human pluripotent stem cells in vitro.Nature protocols · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal muscle tissue engineering is one of the important ways for regenerating functionally defective muscles. Among the myopathies, the Duchenne muscular dystrophy (DMD) is a progressive disease due to mutations of the dystrophin gene leading to progressive myofiber degeneration with severe symptoms. Although current therapies in muscular dystrophy are still very challenging, important progress has been made in materials science and in cellular technologies with the use of stem cells. It is therefore useful to review these advances and the results obtained in a clinical point of view. This article focuses on the differentiation of stem cells into myoblasts, and their application in muscular dystrophy. After an overview of the different stem cells that can be induced to differentiate into the myogenic lineage, we introduce scaffolding materials used for muscular tissue engineering. We then described some widely used methods to differentiate different types of stem cell into myoblasts. We highlight recent insights obtained in therapies for muscular dystrophy. Finally, we conclude with a discussion on stem cell technology. We discussed in parallel the benefits brought by the evolution of the materials and by the expansion of cell sources which can differentiate into myoblasts. We also discussed on future challenges for clinical applications and how to accelerate the translation from the research to the clinic in the frame of DMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.